FY2025 EPS Estimates for Biomea Fusion Cut by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Biomea Fusion in a report released on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($3.91) per share for the year, down from their previous estimate of ($3.17). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion's FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($2.45) EPS.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.19.

BMEA has been the topic of several other reports. D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 target price on shares of Biomea Fusion in a research note on Wednesday, March 19th. Barclays decreased their price objective on shares of Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 2nd. Finally, Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a report on Monday, March 24th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Biomea Fusion presently has a consensus rating of "Buy" and an average price target of $23.91.

Remove Ads

Biomea Fusion Price Performance

NASDAQ BMEA traded down $0.12 during trading on Thursday, hitting $1.90. 341,873 shares of the company's stock traded hands, compared to its average volume of 908,805. Biomea Fusion has a 12-month low of $1.86 and a 12-month high of $13.66. The stock has a fifty day moving average of $3.05 and a two-hundred day moving average of $5.74. The firm has a market cap of $71.20 million, a P/E ratio of -0.47 and a beta of -0.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BMEA. PNC Financial Services Group Inc. lifted its holdings in shares of Biomea Fusion by 14.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 24,005 shares of the company's stock valued at $93,000 after purchasing an additional 3,005 shares during the last quarter. Wexford Capital LP raised its holdings in shares of Biomea Fusion by 2.3% during the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company's stock valued at $517,000 after purchasing an additional 3,007 shares during the last quarter. Geode Capital Management LLC raised its stake in Biomea Fusion by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 601,479 shares of the company's stock valued at $6,076,000 after buying an additional 4,291 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Biomea Fusion by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company's stock valued at $50,000 after purchasing an additional 4,399 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Biomea Fusion by 27.6% during the fourth quarter. JPMorgan Chase & Co. now owns 22,535 shares of the company's stock valued at $87,000 after buying an additional 4,868 shares during the period. Hedge funds and other institutional investors own 96.72% of the company's stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.